One Drink Could Be Harming You More Than You Think — Here’s Why

The rate at which alcohol is processed by the body varies among individuals, potentially explaining differing risks for alcoholism, liver injury, and cancer.

The human body metabolizes a limited amount of alcohol per hour—approximately one standard drink—regardless of consumption volume. Exceeding this capacity results in alcohol accumulation and intoxication. For instance, after one drink, blood alcohol concentration (BAC) may return to zero within one to two hours, but higher intake prolongs this clearance time.

Alcohol enters the bloodstream through absorption in the stomach and intestines, where enzymes initiate its breakdown. Two liver enzymes, alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), sequentially convert alcohol into acetaldehyde and then acetate, facilitating elimination.

Acetaldehyde, although transient in the body, is a highly toxic compound and a recognized carcinogen. While most alcohol metabolism occurs in the liver, minor pathways produce fatty acid ethyl esters (FAEEs), which have been implicated in liver and pancreatic damage. Additionally, a small fraction of alcohol is excreted unchanged via breath and urine, enabling BAC measurement.

The toxic effects of acetaldehyde are particularly pronounced in the liver, where most alcohol metabolism takes place, but also affect the pancreas, brain, and gastrointestinal tract. Research suggests acetaldehyde may contribute not only to tissue damage but also to behavioral and physiological effects associated with alcohol consumption, such as impaired judgment and coordination.

Animal studies administering acetaldehyde have observed incoordination, memory deficits, and drowsiness. Although the brain’s blood-brain barrier typically limits exposure to blood toxins, enzymes like catalase and CYP2E1 can generate acetaldehyde within the brain when large amounts of alcohol are consumed. Furthermore, acetate, a breakdown product of acetaldehyde, crosses into the brain and influences GABA neurotransmission, which can impair motor function.

Factors such as liver size and body mass impact alcohol metabolism rates, but genetic variations in ADH and ALDH enzymes are considered the most significant determinants of metabolic efficiency. Some individuals possess enzyme variants that metabolize alcohol or acetaldehyde faster or slower than others.

For example, individuals with a fast-acting ADH or a slow-acting ALDH enzyme may accumulate toxic acetaldehyde, resulting in adverse effects upon alcohol intake. Women typically have lower ADH activity in the stomach compared to men, leading to higher blood alcohol levels after drinking, which may partly explain their increased vulnerability to alcohol-related liver, heart, and brain damage.

Genetic differences also influence susceptibility to alcohol use disorders. Certain enzyme variants cause acetaldehyde buildup that triggers facial flushing, nausea, and rapid heartbeat even after moderate drinking. This variant is prevalent among people of Chinese, Japanese, and Korean descent, with 36% to 45% experiencing these effects, which may reduce their alcohol consumption and protect against alcoholism. In contrast, this protective gene is rare among individuals of European and African descent. Another variant, ADH1B*3, found in approximately 25% of Black individuals, also offers protection against alcoholism, though some ALDH variants may be linked to increased alcoholism risk in this group.

According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), genetics account for about half the risk of developing alcohol use disorder, with environmental and social factors comprising the remainder. Children of individuals with alcohol use disorder have a higher likelihood of developing similar problems, influenced by both genetic and shared environmental factors.

Research has documented an increase in alcohol use disorders among Japanese individuals carrying the protective ADH1B*2 gene, rising from 2.5% to 13% between 1979 and 1992, indicating that non-genetic factors can override genetic protection. In the United States, Native Americans experience the highest rates of alcohol-related mortality, yet studies show no difference in enzyme activity or metabolism rates compared to Caucasians, suggesting other contributors to alcohol-related issues.

Chronic heavy drinking is associated with numerous health problems, some directly linked to alcohol metabolism and acetaldehyde production. Acetaldehyde’s toxicity correlates with cancers of the mouth, throat, respiratory tract, liver, colon, and breasts. Ironically, individuals with genes that discourage heavy drinking may face higher cancer risks due to increased acetaldehyde production when they consume alcohol.

Because the liver metabolizes most alcohol and produces acetaldehyde, it is especially susceptible to damage. Over 90% of heavy drinkers develop fatty liver disease. The pancreas is also vulnerable due to local alcohol metabolism, but only 10% to 15% of heavy drinkers develop alcoholic pancreatitis, implying additional factors such as smoking, diet, and drinking patterns may influence disease development.

Alcohol intake does not uniformly cause weight gain despite its caloric content. While moderate drinking does not increase weight in lean individuals, studies indicate that adding alcohol to the diets of overweight persons can lead to weight gain.

Alcohol metabolism affects sex hormones differently in men and women. In men, it contributes to testicular injury, reduced testosterone synthesis, and impaired sperm production, potentially causing feminization symptoms like breast enlargement. In women, alcohol metabolism can increase estradiol production and decrease its breakdown, raising estradiol levels, which are linked to higher bone density and lower coronary artery disease risk.

Alcohol also interacts with various medications, altering their metabolism. Chronic heavy drinking activates the CYP2E1 enzyme, which can convert acetaminophen into a toxic compound capable of causing liver damage even at therapeutic doses.

Research funded by the National Institute on Alcohol Abuse and Alcoholism continues to investigate how differences in alcohol metabolism influence drinking behavior and the development of alcohol-related health issues. Understanding these metabolic variations may facilitate the creation of targeted treatments for individuals at risk.

Current evidence-based treatments for alcohol use disorder include psychotherapy, medications, and support groups. Psychotherapy approaches such as cognitive-behavioral therapy, motivational enhancement therapy, contingency management, and mindfulness-based interventions help individuals identify triggers, set goals, and develop coping mechanisms. Medications like acamprosate, disulfiram, and naltrexone may reduce cravings and withdrawal symptoms. Support groups, including 12-step programs, provide encouragement and improve long-term sobriety prospects. Treatment plans are tailored to individual needs, often combining multiple approaches for optimal outcomes.